Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1400-1409.doi: 10.12092/j.issn.1009-2501.2026.10.011
Siyuan ZHANG(
), Xiangqi WANG, Yi YIN(
)
Received:2025-12-17
Revised:2026-03-25
Online:2026-10-26
Published:2026-11-11
Contact:
Yi YIN
E-mail:1370967149@qq.com;413672306@qq.com
CLC Number:
Siyuan ZHANG, Xiangqi WANG, Yi YIN. Research progress on enhancement of immunotherapy sensitivity of lung cancer by PD-1/PD-L1 pathway with traditional Chinese medicine and natural products[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1400-1409.
| 编号 | 天然产物 | 分子式 | 来源 | 细胞动物模型 | 作用机制 | 参考文献 |
| 1 | 山奈酚 | C15H10O6 | 广泛存在于蔬菜、药用植物和水果中 | A549与Lewis肺癌荷瘤小鼠 | 通过直接结合PD-1蛋白,抑制PD-1/PD-L1相互作用从而逆转免疫抑制 | [ |
| 2 | 甘草查酮A | C21H22O4 | 甘草 | A549和 H1299细胞 | 通过清除ROS可有效抑制IFN-γ诱导的PD-L1表达 | [ |
| 3 | 水飞蓟素 | C25H22O10 | 从菊科药用植物水飞蓟种子的种皮 | H3122细胞 | 抑制免疫检查点调节因子PD-L1和EMT调节因子:SLUG, VIM,CD44 | [ |
| 4 | 木犀草素 | C15H10O6 | 广泛存在于蔬菜、药用植物和水果中 | H358细胞异种移植物小鼠肺癌 模型;H358、H460、 H2122和A549细胞 | 阻断PD-1/PD-L1轴,下调PDL1表达 | [ |
| 5 | 槲皮素 | C15H10O7 | 广泛存在于蔬菜、药用植物和水果中 | NCI-H460 cells细胞系、Lewis肺癌荷瘤小鼠 | 通过抑制PD-1/PD-L1相互作用来减弱PD-L1对T细胞的抑制作用 | [ |
| 6 | (-)表没食子儿茶素没食子酸酯 | C22H18O11 | 存在中国绿茶中 | A549、Lu99细胞系4-甲基亚硝基吡啶1-丁酮诱导的A/J肺癌小鼠模型 | 抑制IFN-γ和EGF诱导的非小细胞肺癌细胞中PD-L1的表达 | [ |
| 7 | 杨梅素 | C15H10O8 | 杨梅科、蓼科、报春花科、松科和角豆科植物 | A549、H1650和 H460细胞 | 逆转Jurkat-PD-1 T细胞存活率 | [ |
| 8 | 金合欢素 | C16H12O5 | 广泛存在于金合欢树、洋槐树、大蓟、密蒙花、菊花 | A549和H460细胞系、A549异种移植小鼠肺癌模型 | 上调miR-34a的表达水平,下调体外 NSCLC细胞和体内肿瘤的PD-L1表达水平 | [ |
Table 1 Basic information and mechanism of action of eight flavonoids
| 编号 | 天然产物 | 分子式 | 来源 | 细胞动物模型 | 作用机制 | 参考文献 |
| 1 | 山奈酚 | C15H10O6 | 广泛存在于蔬菜、药用植物和水果中 | A549与Lewis肺癌荷瘤小鼠 | 通过直接结合PD-1蛋白,抑制PD-1/PD-L1相互作用从而逆转免疫抑制 | [ |
| 2 | 甘草查酮A | C21H22O4 | 甘草 | A549和 H1299细胞 | 通过清除ROS可有效抑制IFN-γ诱导的PD-L1表达 | [ |
| 3 | 水飞蓟素 | C25H22O10 | 从菊科药用植物水飞蓟种子的种皮 | H3122细胞 | 抑制免疫检查点调节因子PD-L1和EMT调节因子:SLUG, VIM,CD44 | [ |
| 4 | 木犀草素 | C15H10O6 | 广泛存在于蔬菜、药用植物和水果中 | H358细胞异种移植物小鼠肺癌 模型;H358、H460、 H2122和A549细胞 | 阻断PD-1/PD-L1轴,下调PDL1表达 | [ |
| 5 | 槲皮素 | C15H10O7 | 广泛存在于蔬菜、药用植物和水果中 | NCI-H460 cells细胞系、Lewis肺癌荷瘤小鼠 | 通过抑制PD-1/PD-L1相互作用来减弱PD-L1对T细胞的抑制作用 | [ |
| 6 | (-)表没食子儿茶素没食子酸酯 | C22H18O11 | 存在中国绿茶中 | A549、Lu99细胞系4-甲基亚硝基吡啶1-丁酮诱导的A/J肺癌小鼠模型 | 抑制IFN-γ和EGF诱导的非小细胞肺癌细胞中PD-L1的表达 | [ |
| 7 | 杨梅素 | C15H10O8 | 杨梅科、蓼科、报春花科、松科和角豆科植物 | A549、H1650和 H460细胞 | 逆转Jurkat-PD-1 T细胞存活率 | [ |
| 8 | 金合欢素 | C16H12O5 | 广泛存在于金合欢树、洋槐树、大蓟、密蒙花、菊花 | A549和H460细胞系、A549异种移植小鼠肺癌模型 | 上调miR-34a的表达水平,下调体外 NSCLC细胞和体内肿瘤的PD-L1表达水平 | [ |
| 编号 | 天然产物 | 分子式 | 来源 | 细胞动物模型 | 作用机制 | 参考文献 |
| 1 | 小檗碱 | C20H18NO4 | 黄连 Coptis chinensis Franch | A549,H157,H358, H460,H1299,H1975,LLC和Jurkat(E6-1)细胞系,LLC皮下瘤小鼠与BALB/c裸鼠 | 通过降低癌细胞中PD-L1的水平,增强肿瘤细胞对共培养T细胞的敏感性 | [ |
| 2 | 石斛碱 | C16H25NO2 | 金钗石斛Dendrobium nobile Lindl. | A549细胞系、 BALB/c裸鼠 | 显著降低肿瘤组织中PD-L1+、CD11b+、CD25+FOXP3+细胞百分比,提高CD4+、CD8+细胞百分比,提高肿瘤组织中IL-2、IFN-γ、TGF-β水平 | [ |
| 3 | 吴茱萸次碱 | C18H13N3O | 吴茱萸 Euodia rutaecarpa(Juss.)Benth. | A549和H358细胞系 | 显著激活STING 信号通路,降低PD-L1在癌细胞的表达,激活CD8+T细胞 | [ |
| 4 | 汉防已乙素 | C37H40N2O6 | 粉防己 Stephania tetrandra S. Moore | NCI-H1299、NCI-H1975、A549、NCI-H1650和 NCI-H446细胞系 | 联合PD-1阻断,增加CD8+T细胞介导的细胞毒性 | [ |
| 5 | 苦参总碱 | C15H24N2O | 苦参 Sophora flavescens Ait. | H1299和LLC细胞系、LLC皮下瘤小鼠模型 | 增强了抗PD-L1/TGF-β双特异性抗体,抑制自噬和活性氧的产生,从而诱导肿瘤细胞凋亡,阻止肿瘤生长 | [ |
| 6 | 苦豆碱 | C15H24N2 | 苦豆子 Sophora alopecuroides L | H1299和LLC细胞系、LLC皮下瘤小鼠模型 | 增强了抗PD-L1/TGF-β双特异性抗体,抑制自噬和活性氧的产生,从而诱导肿瘤细胞凋亡,阻止肿瘤生长 | [ |
| 7 | 菲卡普临辛 | C18H11ClN2O | 海绵 Spongia | A549细胞系、LLC小鼠模型 | 诱导细胞凋亡和铁死亡,在体内提高抗PD-1免疫治疗的敏感性,从而发挥抗癌作用 | [ |
Table 2 Basic information and mechanism of action of seven alkaloid compounds
| 编号 | 天然产物 | 分子式 | 来源 | 细胞动物模型 | 作用机制 | 参考文献 |
| 1 | 小檗碱 | C20H18NO4 | 黄连 Coptis chinensis Franch | A549,H157,H358, H460,H1299,H1975,LLC和Jurkat(E6-1)细胞系,LLC皮下瘤小鼠与BALB/c裸鼠 | 通过降低癌细胞中PD-L1的水平,增强肿瘤细胞对共培养T细胞的敏感性 | [ |
| 2 | 石斛碱 | C16H25NO2 | 金钗石斛Dendrobium nobile Lindl. | A549细胞系、 BALB/c裸鼠 | 显著降低肿瘤组织中PD-L1+、CD11b+、CD25+FOXP3+细胞百分比,提高CD4+、CD8+细胞百分比,提高肿瘤组织中IL-2、IFN-γ、TGF-β水平 | [ |
| 3 | 吴茱萸次碱 | C18H13N3O | 吴茱萸 Euodia rutaecarpa(Juss.)Benth. | A549和H358细胞系 | 显著激活STING 信号通路,降低PD-L1在癌细胞的表达,激活CD8+T细胞 | [ |
| 4 | 汉防已乙素 | C37H40N2O6 | 粉防己 Stephania tetrandra S. Moore | NCI-H1299、NCI-H1975、A549、NCI-H1650和 NCI-H446细胞系 | 联合PD-1阻断,增加CD8+T细胞介导的细胞毒性 | [ |
| 5 | 苦参总碱 | C15H24N2O | 苦参 Sophora flavescens Ait. | H1299和LLC细胞系、LLC皮下瘤小鼠模型 | 增强了抗PD-L1/TGF-β双特异性抗体,抑制自噬和活性氧的产生,从而诱导肿瘤细胞凋亡,阻止肿瘤生长 | [ |
| 6 | 苦豆碱 | C15H24N2 | 苦豆子 Sophora alopecuroides L | H1299和LLC细胞系、LLC皮下瘤小鼠模型 | 增强了抗PD-L1/TGF-β双特异性抗体,抑制自噬和活性氧的产生,从而诱导肿瘤细胞凋亡,阻止肿瘤生长 | [ |
| 7 | 菲卡普临辛 | C18H11ClN2O | 海绵 Spongia | A549细胞系、LLC小鼠模型 | 诱导细胞凋亡和铁死亡,在体内提高抗PD-1免疫治疗的敏感性,从而发挥抗癌作用 | [ |
| 编号 | 天然产物 | 分子式 | 来源 | 细胞动物模型 | 作用机制 | 参考文献 |
| 1 | 人参皂苷Rg3 | C42H72O13 | 人参 Panax ginseng C.A.Mey | A549和A549/DDP 细胞系 | NF-κB p65和Akt | [ |
| 2 | 人参皂苷RH2 | C36H62O8 | 人参 Panax ginseng C.A.Mey | A549细胞系 | 影响PD-1和PD-L1的表达抑制免疫逃逸,降低肺癌A549细胞的行为 | [ |
| 3 | 人参皂苷RK1 | C42H70O12 | 人参 Panax ginseng C.A.Mey | A549细胞系 | 通过抑制NF-κB信号传导降低肺腺癌细胞中PD-L1的高表达 | [ |
| 4 | 人参皂苷Rb1 | C54H92O23 | 人参 Panax ginseng C.A.Mey | PI3K突变的A549细胞系、344SQ_R cells耐药细胞系,皮下瘤裸鼠 | 调控PI3K/AKT/mTOR信号通路并诱导免疫微环境重塑 | [ |
| 5 | 桔梗皂苷D | C57H92O28 | 桔梗属大花 (雅克)A.DC | LLC皮下瘤小鼠模型 | 降低PD-1 表达,缓解 CD8?T细胞耗竭 | [ |
| 6 | 三七皂苷R1 | C47H80O18 | 三七 Panax notoginseng (Burk.) F.H. | LLC皮下瘤小鼠模型 | 通过SERPINE1下调来增强化疗卡铂和免疫检查点阻断剂 | [ |
| 7 | 黄芪甲苷IV | C41H68O14 | 黄芪 Astragalus membranaceus(Fisch.)Bge. var. | LLC皮下瘤小鼠模型 | 影响肿瘤内TME和促生存信号通路的免疫细胞浸润,增强抗PD-1的抗肿瘤作用 | [ |
| 8 | 罗汉松内酯E | C19H24O6 | 罗汉松 Podocarpus macrophyllus (Thunb.) D. Don | LLC and 4T1细胞系、4T1皮下肿瘤模型 | 通过激活JNK-c-Jun轴上调肺癌细胞中PD-L1的表达 | [ |
Table 3 Basic information and mechanism of action of 8 terpenoids
| 编号 | 天然产物 | 分子式 | 来源 | 细胞动物模型 | 作用机制 | 参考文献 |
| 1 | 人参皂苷Rg3 | C42H72O13 | 人参 Panax ginseng C.A.Mey | A549和A549/DDP 细胞系 | NF-κB p65和Akt | [ |
| 2 | 人参皂苷RH2 | C36H62O8 | 人参 Panax ginseng C.A.Mey | A549细胞系 | 影响PD-1和PD-L1的表达抑制免疫逃逸,降低肺癌A549细胞的行为 | [ |
| 3 | 人参皂苷RK1 | C42H70O12 | 人参 Panax ginseng C.A.Mey | A549细胞系 | 通过抑制NF-κB信号传导降低肺腺癌细胞中PD-L1的高表达 | [ |
| 4 | 人参皂苷Rb1 | C54H92O23 | 人参 Panax ginseng C.A.Mey | PI3K突变的A549细胞系、344SQ_R cells耐药细胞系,皮下瘤裸鼠 | 调控PI3K/AKT/mTOR信号通路并诱导免疫微环境重塑 | [ |
| 5 | 桔梗皂苷D | C57H92O28 | 桔梗属大花 (雅克)A.DC | LLC皮下瘤小鼠模型 | 降低PD-1 表达,缓解 CD8?T细胞耗竭 | [ |
| 6 | 三七皂苷R1 | C47H80O18 | 三七 Panax notoginseng (Burk.) F.H. | LLC皮下瘤小鼠模型 | 通过SERPINE1下调来增强化疗卡铂和免疫检查点阻断剂 | [ |
| 7 | 黄芪甲苷IV | C41H68O14 | 黄芪 Astragalus membranaceus(Fisch.)Bge. var. | LLC皮下瘤小鼠模型 | 影响肿瘤内TME和促生存信号通路的免疫细胞浸润,增强抗PD-1的抗肿瘤作用 | [ |
| 8 | 罗汉松内酯E | C19H24O6 | 罗汉松 Podocarpus macrophyllus (Thunb.) D. Don | LLC and 4T1细胞系、4T1皮下肿瘤模型 | 通过激活JNK-c-Jun轴上调肺癌细胞中PD-L1的表达 | [ |
| 编号 | 天然产物 | 分子式 | 分类 | 来源 | 细胞动物模型 | 作用机制 | 参考文献 |
| 1 | 白藜芦醇 | C14H12O3 | 多酚类 | 广泛存在于蔬菜、药用植物和水果中 | A549和H1299 细胞系 | 通过激活Wnt信号通路来调节PD-L1的表达,从而抑制抗肿瘤免疫 | [ |
| 2 | 醉茄素A | C28H38O6 | 甾体内酯类 | 印 度 人 参 Withania somnifera (L.)Duna | Lewis肺癌细胞小鼠模型;H1650 和 A549细胞 | 可激活NSCLC细胞的ICD通路,从而上调PD-L1的表达 | [ |
| 3 | 红景天苷 | C14H20O7 | 苯丙烷类苷类 | 红景天 | A549异种移植小鼠肺癌模型,A549细胞 | 抑制PD-L1,促进CD8+T细胞的免疫活性 | [ |
| 4 | 和厚朴酚 | C18H18O2 | 联苯型木脂素 | 木兰属植物 | H460和A549 以及小鼠 Lewis肺癌细胞系、 尾静脉注射LL2细胞建立小鼠肺癌模型 | Lipo-HNK和抗PD-1疗法的组合导致CD8+T细胞浸润和激活增加,从而增强整体抗肿瘤免疫反应 | [ |
| 5 | 三白脂素A | C42H52O11 | 木脂素类 | 龙脑 Saururus cernuus L. | A549细胞系、A549 异种移植小鼠肺癌模型 | 与抗PD-1抗体协同发挥抗肿瘤活性 | [ |
Table 4 Basic information and mechanism of action of five other types of compounds
| 编号 | 天然产物 | 分子式 | 分类 | 来源 | 细胞动物模型 | 作用机制 | 参考文献 |
| 1 | 白藜芦醇 | C14H12O3 | 多酚类 | 广泛存在于蔬菜、药用植物和水果中 | A549和H1299 细胞系 | 通过激活Wnt信号通路来调节PD-L1的表达,从而抑制抗肿瘤免疫 | [ |
| 2 | 醉茄素A | C28H38O6 | 甾体内酯类 | 印 度 人 参 Withania somnifera (L.)Duna | Lewis肺癌细胞小鼠模型;H1650 和 A549细胞 | 可激活NSCLC细胞的ICD通路,从而上调PD-L1的表达 | [ |
| 3 | 红景天苷 | C14H20O7 | 苯丙烷类苷类 | 红景天 | A549异种移植小鼠肺癌模型,A549细胞 | 抑制PD-L1,促进CD8+T细胞的免疫活性 | [ |
| 4 | 和厚朴酚 | C18H18O2 | 联苯型木脂素 | 木兰属植物 | H460和A549 以及小鼠 Lewis肺癌细胞系、 尾静脉注射LL2细胞建立小鼠肺癌模型 | Lipo-HNK和抗PD-1疗法的组合导致CD8+T细胞浸润和激活增加,从而增强整体抗肿瘤免疫反应 | [ |
| 5 | 三白脂素A | C42H52O11 | 木脂素类 | 龙脑 Saururus cernuus L. | A549细胞系、A549 异种移植小鼠肺癌模型 | 与抗PD-1抗体协同发挥抗肿瘤活性 | [ |
Fig.2 The representative mechanism diagram of traditional Chinese medicine and natural products intervening in lung cancer through the PD-1/PD-L1 pathway
| 1 | Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74 (3): 229- 263. |
| 2 |
Eng L, Evans WK, Eisele M, et al. The international association for the study of lung cancer staging project: the impact of smoking status on lung cancer staging in the ninth edition of the TNM classification[J]. J Thorac Oncol, 2025, 20 (10): 1441- 1458.
doi: 10.1016/j.jtho.2025.07.002 |
| 3 |
Wang B, Guo H, Xu H, et al. Research progress and challenges in the treatment of central nervous system metastasis of non-small cell lung cancer[J]. Cells, 2021, 10 (10): 2620.
doi: 10.3390/cells10102620 |
| 4 |
李松珍, 邵天航, 姚舒洋. 非小细胞肺癌寡转移的研究进展及挑战[J]. 中国肺癌杂志, 2025, 28 (6): 467- 471.
doi: 10.3779/j.issn.1009-3419.2025.102.22 |
| 5 | Pang K, Shi ZD, Wei LY, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade[J]. Drug Resist Updat, 2022, 66, 100907. |
| 6 |
Kluger H, Barrett JC, Gainor JF, et al. Society for immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors[J]. J Immunother Cancer, 2023, 11 (3): e005921.
doi: 10.1136/jitc-2022-005921 |
| 7 |
Ri MH, Ma J, Jin X. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer[J]. J Ethnopharmacol, 2021, 281, 114370.
doi: 10.1016/j.jep.2021.114370 |
| 8 |
Li L, Pu H, Zhang X, et al. Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer[J]. Crit Rev Oncol Hematol, 2025, 209, 104683.
doi: 10.1016/j.critrevonc.2025.104683 |
| 9 |
Zhou Y, Chen C, Zhang X, et al. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis[J]. J Immunother Cancer, 2018, 6 (1): 155.
doi: 10.1186/s40425-018-0477-9 |
| 10 |
Li X, Yan S, Yang J, et al. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a network analysis of randomized controlled trials[J]. Front Oncol, 2021, 10, 574752.
doi: 10.3389/fonc.2020.574752 |
| 11 | Gao P, Li X, Duan Z, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade: advances in molecular mechanisms and therapeutic strategies [J]. MedComm (2020), 2025, 6(8): e70274. |
| 12 |
Zhao Y, Harrison DL, Song Y, et al. Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells[J]. Cell Rep, 2018, 24 (2): 379- 390.
doi: 10.1016/j.celrep.2018.06.054 |
| 13 |
Yu ZZ, Liu YY, Zhu W, et al. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers[J]. J Immunother Cancer, 2023, 11 (3): e006345.
doi: 10.1136/jitc-2022-006345 |
| 14 | Li K, Tian HQ. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy[J]. J Drug Target, 2018, 27 (3): 244- 256. |
| 15 |
Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers[J]. Front Immunol, 2022, 13, 964442.
doi: 10.3389/fimmu.2022.964442 |
| 16 | Awad MM, Gadgeel SM, Borghaei H, et al. Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC[J]. J Thorac Oncol, 2020, 16 (1): 162- 168. |
| 17 |
Renaud E, Ricordel C, Corre R, et al. Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)[J]. Transl Lung Cancer Res, 2023, 12 (2): 266- 276.
doi: 10.21037/tlcr-22-556 |
| 18 |
Yao P, Liang S, Liu Z, et al. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer[J]. Front Immunol, 2024, 15, 1343316.
doi: 10.3389/fimmu.2024.1343316 |
| 19 |
Shen N, Wang TF, Gan Q, et al. Plant flavonoids: classification, distribution, biosynthesis, and antioxidant activity[J]. Food Chem, 2022, 383, 132531.
doi: 10.1016/j.foodchem.2022.132531 |
| 20 |
Zanoaga O, Braicu C, Jurj A, et al. Progress in research on the role of flavonoids in lung cancer[J]. Int J Mol Sci, 2019, 20 (17): 4291.
doi: 10.3390/ijms20174291 |
| 21 |
Sun Q, Liu Q, Zhou X, et al. Flavonoids regulate tumor-associated macrophages -From structure-activity relationship to clinical potential (Review)[J]. Pharmacol Res, 2022, 184, 106419.
doi: 10.1016/j.phrs.2022.106419 |
| 22 |
Kim JH, Kim YS, Choi JG, et al. Kaempferol and its glycoside, kaempferol 7-O-rhamnoside, inhibit PD-1/PD-L1 interaction in vitro[J]. Int J Mol Sci, 2020, 21 (9): 3239.
doi: 10.3390/ijms21093239 |
| 23 |
Jiang ZB, Wang WJ, Xu C, et al. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer[J]. Cancer Lett, 2021, 515, 36- 48.
doi: 10.1016/j.canlet.2021.05.019 |
| 24 |
Zhang JL, Liu XQ, Zhang GY, et al. To explore the effect of kaempferol on non-small cell lung cancer based on network pharmacology and molecular docking[J]. Front Pharmacol, 2023, 14, 1148171.
doi: 10.3389/fphar.2023.1148171 |
| 25 |
Li X, Bai Y, Zhou JW, et al. Luteolin targets peroxiredoxin 2 to augment T-cell-mediated cytotoxicity and suppress lung adenocarcinoma progression[J]. Eur J Pharmacol, 2025, 1004, 177984.
doi: 10.1016/j.ejphar.2025.177984 |
| 26 |
Jing L, Lin JR, Yang Y, et al. Quercetin inhibiting the PD-1/PD-L1 interaction for immune-enhancing cancer chemopreventive agent[J]. Phytother Res, 2021, 35 (11): 6441- 6451.
doi: 10.1002/ptr.7297 |
| 27 |
Jasemi S, Khazaei H, Fakhri S, et al. Quercetin modulates the signalling pathways and therapeutic targets in the pathophysiology of lung cancer: a systematic review[J]. Lett Drug Des Discov, 2024, 21 (14): 2903- 2915.
doi: 10.2174/1570180820666230719121525 |
| 28 |
Yuan LW, Jiang XM, Xu YL, et al. Licochalcone a inhibits interferon-gamma- induced programmed death-ligand 1 in lung cancer cells[J]. Phytomedicine, 2020, 80, 153394.
doi: 10.1016/j.phymed.2020.153394 |
| 29 |
Rawangkan A, Wongsirisin P, Namiki K, et al. Green Tea catechin is an alternative immune checkpoint inhibitor that inhibits PD-L1 expression and lung tumor growth[J]. Molecules, 2018, 23 (8): 2071.
doi: 10.3390/molecules23082071 |
| 30 |
Cuyàs E, Pérez-Sánchez A, Micol V, et al. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer[J]. Cell Cycle, 2016, 15 (24): 3413- 3418.
doi: 10.1080/15384101.2016.1245249 |
| 31 |
Bosch-Barrera J, Sais E, Teixidor-Vilà E, et al. The STAT3/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report[J]. Front Med (Lausanne), 2025, 12, 1612327.
doi: 10.3389/fmed.2025.1612327 |
| 32 |
Chen YC, He XL, Qi L, et al. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells[J]. Biochem Pharmacol, 2022, 197, 114940.
doi: 10.1016/j.bcp.2022.114940 |
| 33 |
Li J, Zhong XM, Zhao YS, et al. Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo[J]. Sci Rep, 2024, 14 (1): 2348.
doi: 10.1038/s41598-024-52896-6 |
| 34 | Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer[J]. Annu Rev Physiol, 2019, 82, 103- 126. |
| 35 |
Mondal A, Gandhi A, Fimognari C, et al. Alkaloids for cancer prevention and therapy: Current progress and future perspectives[J]. Eur J Pharmacol, 2019, 858, 172472.
doi: 10.1016/j.ejphar.2019.172472 |
| 36 |
Zhang S, Zhou L, Zhang M, et al. Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin[J]. Front Pharmacol, 2020, 10, 1658.
doi: 10.3389/fphar.2019.01658 |
| 37 |
Chen S, Ma S, Wang H, et al. Unraveling the mechanism of alkaloids from sophora alopecuroides linn combined with immune checkpoint blockade in the treatment of non-small cell lung cancer based on systems pharmacology[J]. Bioorg Med Chem, 2022, 64, 116724.
doi: 10.1016/j.bmc.2022.116724 |
| 38 |
Li L, Nong J, Li J, et al. Dendrobine suppresses tumor growth by regulating the PD-1/PD-L1 checkpoint pathway in lung cancer[J]. Curr Cancer Drug Targets, 2025, 25 (9): 1108- 1117.
doi: 10.2174/0115680096305416240820040314 |
| 39 |
Jiang ZB, He QH, Kang LP, et al. Rutecarpine suppresses non-small cell lung cancer progression through activating the STING pathway and elevating CD8+T cells[J]. Chem Biol Drug Des, 2025, 105 (2): e70070.
doi: 10.1111/cbdd.70070 |
| 40 |
Tan Y, Zhu QC, Yang ML, et al. Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer[J]. Pharmacol Res, 2024, 207, 107314.
doi: 10.1016/j.phrs.2024.107314 |
| 41 |
Song Y, Jiang YX, Guan JY, et al. Fangchinoline-mediated autophagy inhibition amplifies antigen presentation and PD-1 blockade efficacy in lung cancer[J]. Acta Pharmacol Sin, 2025, 46 (10): 2751- 2764.
doi: 10.1038/s41401-025-01541-7 |
| 42 |
Zhu LL, Huang SS, Li JH, et al. Sophoridine inhibits lung cancer cell growth and enhances cisplatin sensitivity through activation of the p53 and Hippo signaling pathways[J]. Gene, 2020, 742, 144556.
doi: 10.1016/j.gene.2020.144556 |
| 43 |
Guo WN, Zhou HF, Wang JB, et al. Aloperine suppresses cancer progression by interacting with VPS4A to inhibit autophagosome-lysosome fusion in NSCLC[J]. Adv Sci (Weinh), 2024, 11 (31): e2308307.
doi: 10.1002/advs.202308307 |
| 44 |
Luo L, Xu G. Fascaplysin induces apoptosis and ferroptosis, and enhances Anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) by promoting PD-L1 expression[J]. Int J Mol Sci, 2022, 23 (22): 13774.
doi: 10.3390/ijms232213774 |
| 45 | Sun H, Zhang LJ, Sui BW, et al. The effect of terpenoid natural Chinese medicine molecular compound on lung cancer treatment[J]. Evid Based Complement Alternat Med, 2021, 2021, 3730963. |
| 46 | Singh A, Debnath R, Sharma A, et al. Exploring the potential of terpenoids as a possible treatment for cancer: structure-activity relationship and mechanistic studies[J]. Curr Med Chem, 2024, 31 (24): 2799- 2820. |
| 47 |
Li M, Wang X, Wang Y, et al. Strategies for remodeling the tumor microenvironment using active ingredients of ginseng-a promising approach for cancer therapy[J]. Front Pharmacol, 2021, 12, 797634.
doi: 10.3389/fphar.2021.797634 |
| 48 |
Jiang ZS, Yang YF, Yang YL, et al. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune[J]. Biomed Pharmacother, 2017, 96, 378- 383.
doi: 10.1016/j.biopha.2017.09.129 |
| 49 | Cao BX, Wei Q, Feng H, He Z. Mesoporous silica nano-modified Ginsenoside Rh2 promote tumor immunosuppression and inhibit lung cancer development through the PD-1/PD-L1 pathway[J]. Ann Clin Lab Sci, 2024, 54 (5): 597- 603. |
| 50 |
Hu ML, Yang J, Qu LL, et al. Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma[J]. Food Funct, 2020, 11 (1): 456- 471.
doi: 10.1039/C9FO02166C |
| 51 |
Jin XY, Wuyun THS, Zhang Y, et al. Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems[J]. J Nanobiotechnology, 2025, 23 (1): 443.
doi: 10.1186/s12951-025-03456-1 |
| 52 |
Yang RJ, Pei TL, Huang RF, et al. Platycodon grandiflorum triggers antitumor immunity by restricting PD-1 expression of CD8+T cells in local tumor microenvironment[J]. Front Pharmacol, 2022, 13, 774440.
doi: 10.3389/fphar.2022.774440 |
| 53 | Wang YH, Wang P, Liu JQ, et al. Panax notoginseng saponins enhance chemotherapy carboplatin and immune checkpoint blockades PD1ab by modulating SERPINE1 downregulation in LUAD[J]. Pharmacogn Mag, 2025, 21 (4): 1- 11. |
| 54 |
Wu T, Wu SK, Gao H, et al. Astragaloside IV augments anti-PD-1 therapy to suppress tumor growth in lung cancer by remodeling the tumor microenvironment[J]. Eur J Histochem, 2024, 68 (4): 4098.
doi: 10.4081/ejh.2024.4098 |
| 55 | Chen YC, Huang MY, Zhang LL, et al. Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells[J]. Chin J Nat Med, 2020, 18 (7): 517- 525. |
| 56 |
Yang MM, Li ZY, Tao JP, et al. Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells[J]. J Cancer Res Clin Oncol, 2021, 147 (4): 1101- 1113.
doi: 10.1007/s00432-021-03510-z |
| 57 |
Khalil R, Green RJ, Sivakumar K, et al. Withaferin A increases the effectiveness of immune checkpoint blocker for the treatment of non-small cell lung cancer[J]. Cancers (Basel), 2023, 15 (12): 3089.
doi: 10.3390/cancers15123089 |
| 58 |
Jin GL, Ma M, Yang CY, et al. Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624-mediated PD-L1 pathway[J]. Thorac Cancer, 2023, 14 (24): 2493- 2503.
doi: 10.1111/1759-7714.15034 |
| 59 |
Luo LX, Wu T, Ji MR, et al. Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer[J]. Int Immunopharmacol, 2024, 133, 112098.
doi: 10.1016/j.intimp.2024.112098 |
| 60 |
Lang LW, Liu XY, Li Y, et al. A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth[J]. PLos One, 2014, 9 (6): e99584.
doi: 10.1371/journal.pone.0099584 |
| 61 | Zhang Y, Liu H, Wang L, et al. Natural-derived compounds reshape anti-tumor immunity to overcome PD-1/PD-L1 resistance in non-small-cell lung cancer[J]. Phytomedicine, 2025, 132, 155871. |
| 62 |
Li HF, Seeram NP, Liu C, et al. Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1[J]. Front Oncol, 2022, 12, 995461.
doi: 10.3389/fonc.2022.995461 |
| 63 | Qu JJ, Mei QH, Liu L, et al. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer [J]. Ther Adv Med Oncol, 2021, 13: 1758835921992968 |
| 64 |
Xu MT, Lin XW, Xu HC, et al. Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1[J]. J Clin Invest, 2026, 136 (3): e197592.
doi: 10.1172/JCI197592 |
| 65 | Huang QY, Zang XL, Jin XU, et al. Discovery of PD-L1 peptide inhibitors from ascidian enzymatic hydrolysates by affinity ultrafiltration coupled to nanoLC-MS/MS[J]. Mar Drugs, 2026, 23 (1): 37. |
| 66 | Ahmed SF, Hossain MS, Mondal A, et al. In silico identification of promising PD-L1 inhibitors from selected Indian medicinal plants for treatment of triple negative breast cancer[J]. Plos One, 2026, 11 (3): e0327475. |
| 67 | Xia LL, Liu YY, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions [J]. Oncologist, 2019, 24(suppl 1): S31-S41. |
| 68 |
Chen L, Zheng Y, Zhou M, et al. Plant-derived bioactive molecules potentiate anti-PD-1 immunotherapy in lung cancer: molecular mechanisms and pre-clinical evidence[J]. Int J Mol Sci, 2024, 25 (20): 11023.
doi: 10.3390/ijms252011023 |
| 69 |
Kumar GS, Moustafa M, Sahoo AK, et al. Computational investigations on the natural small molecule as an inhibitor of programmed death ligand 1 for cancer immunotherapy[J]. Life (Basel), 2022, 12 (5): 659.
doi: 10.3390/life12050659 |
| 70 |
Bulbul EO, Okur NU. Difficulties in using natural herbal substances and their current use in some pharmaceutical dosage forms[J]. Curr Pharm Des, 2025, 31 (28): 2252- 2266.
doi: 10.2174/0113816128346715250120074519 |
| [1] | Zishun GAO, Yunxia LI. Research progress in immunotherapy and emerging technologies for osteoarthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(9): 1286-1296. |
| [2] | Rong WANG, Yixin ZHOU, Jing XUE, Jiqing HAO, Fan HUANG, Jianghao XING. Efficacy and safety of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of advanced biliary malignancies in the first line of chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(8): 1076-1084. |
| [3] | Yuanjun ZHANG, Jing MA, Juxiang LIU, Jinxin QUAN. Advances in the molecular pharmacological mechanisms of Chinese herbal monomers targeting diabetes-related signal transduction pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(8): 1135-1143. |
| [4] | Wei LIU, Wei ZHANG. Gut microbiota and colorectal cancer: advances from pathogenic mechanisms to therapeutic interventions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 937-947. |
| [5] | Xixi XU, Qing WANG, Yuanyuan SHI, Qiaoxue WANG, Huan LONG. Research progress in traditional Chinese medicine regulating pyroptosis for treating rheumatoid arthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 965-974. |
| [6] | Xiao XU, Shuailin WANG, Xin QIAN, Yi YAO, Zhangyu WANG, Xiaoyi ZHU, Qing MAO, Qi GUO. Research progress on the treatment of diabetic cardiomyopathy with traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 764-773. |
| [7] | Ailin LU, Mengrui YUAN, Yongqing WU, Hongyi LIU. Progress of Chinese medicine intervention in HMGB1 pathway to improve type 2 diabetes mellitus and its complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 827-835. |
| [8] | Qun LI, Xinyue ZHANG, Shuo QI, Jin TAN. Research progress on the mechanism of TGF-β1/Smads signaling pathway in oral submucous fibrosis and regulation of traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 666-674. |
| [9] | Mina GAO, Liya YANG, Shangying DUAN, Xinlu CHEN, Xiaoya LI, Bo QIAO, Yueying WU. Research progress on the prevention and treatment of high-altitude diseases by traditional Chinese medicine based on the "lung-brain axis" [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 675-682. |
| [10] | Qiankun DING, Dejie ZENG, Xiaqing SUN, Jili ZHAO, Qi SUN, Hongwei ZHU. Research progress on natural products in the treatment of autism spectrum disorder [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 700-708. |
| [11] | Ying ZHOU, Juntong LIU, Qingfeng WANG, Yufeng YANG, Yan SHI. Research progress on pharmacological mechanism of traditional Chinese medicine targeting type 2 diabetes related pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 500-508. |
| [12] | Liya SUN, Jiaxin LI, Guiyan SUN, Zhichao CHEN, Qingfeng WANG, Yufeng YANG, Yan SHI. Research progress of traditional Chinese medicine in the prevention and treatment of diabetic nephropathy based on intestinal flora and branched-chain amino acids [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 527-535. |
| [13] | Yu ZHANG, Wenbin XU, Yueqin WANG. Progress of N6-methyladenosine modification in regulating the tumor immune microenvironment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 543-550. |
| [14] | Yuanyuan HUANG, Lingzhun WANG. Research progress in the intervention of myocardial fibrosis by regulating signal pathways with traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 372-381. |
| [15] | Xiaoyu YIN, Ming LU, Zefang YU, Guoxun PANG. A novel drug for the treatment of METex14 skipping mutation non-small cell lung cancer—Glumetinib [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 420-427. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||